Key result
Increased peak serum VEGF levels were not significantly associated with the occurrence of major adverse cardiovascular events 30 days after acute myocardial infarction (OR 0.959).
Why the study?
VEGF plays an important role in regeneration, vascular repair, and coronary collateral circulation during AMI, but its correlation with PBMC and MACE needed investigation.
Does increased serum VEGF level correlate with 30-day Major Adverse Cardiovascular Events (MACE) in patients with Acute Myocardial Infarction?
Cohort (n=20)
No
Does increased serum VEGF level correlate with 30-day Major Adverse Cardiovascular Events (MACE) in patients with Acute Myocardial Infarction?
Odds Ratio: 0.959 (95% CI 0.885–1.039)
p-value: p=0.302
Serum VEGF levels increase following acute myocardial infarction but do not significantly correlate with 30-day major adverse cardiovascular events in this small cohort.
VEGF elevation may link to MACE risk via PBMC in AMI; leaves open prognostic validation in larger cohorts.
Vascular Endothelial Growth Factor (VEGF) plays an important role in the process of regeneration and vascular repair. Atherogenesis and angiogenesis contribute to the formation of coronary collateral circulation as an alternative source of blood supply during the repairing process of Acute Myocardial Infarction (AMI). This study aimed to investigate the elevation of VEGF and its correlation to Peripheral Blood Mononuclear Cells (PBMC) and Major Adverse Cardiovascular st nd th Events (MACE). Serum VEGF measurements were carried out on 1 , 2 , and the 5 -day onset of angina on 20 patients using st th Chemwell Analyzer based on ELISA method. PBMC was counted on days 1 and 5 according to CBC results from Automatic Cell Counter Sysmex XN-1000i. The major adverse cardiovascular event was recorded 30 days after AMI onset. It was found nd that serum VEGF level in this study was 169.3±34.5 pg/mL on the 1st day, 217.0±49.7 pg/mL on the 2 day, and th th 249.2±48.5 pg/mL on the 5 day. Serum VEGF levels increased gradually and the highest value was found on the 5 day st (p=0.000). There was no correlation between elevated serum VEGF levels with PBMC on the 1 day (p=0.429, r=-0.035) and th the 5 day of AMI (p=0.225, r=+0.081). There was no correlation between elevated serum VEGF levels with incidence of MACE on 30 days after onset of AMI (OR=0.959, 95% CI, p=0.302). Serum VEGF concentrations are increased in Acute Myocardial Infarction and can be used as a marker of myocardial injury. However, this study was unable to prove its role in the outcome of AMI
No takes yet. Share an insight, caveat, or question.
Youvella et al. (2021) conducted a cohort in Acute Myocardial Infarction (n=20). Increased peak serum VEGF levels vs. Lower serum VEGF levels was evaluated on Major Adverse Cardiovascular Events (MACE) at 30 days (OR 0.959, 95% CI 0.885-1.039, p=0.302). Increased peak serum VEGF levels were not significantly associated with the occurrence of major adverse cardiovascular events 30 days after acute myocardial infarction (OR 0.959).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: